The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:431-433 January 24, 2008 Number 4
NextNext

Primary Percutaneous Coronary Intervention

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Nallamothu, B. K.
-PubMed Citation
To the Editor: Several studies have evaluated the role of combination medical therapies administered upstream of primary percutaneous intervention (PCI). As noted in the review of the time to treatment in PCI, by Nallamothu et al. (Oct. 18 issue),1 these trials have failed to demonstrate a survival benefit from either full-dose fibrinolysis plus PCI or reduced-dose fibrinolysis in combination with glycoprotein IIb/IIIa antagonists plus PCI in patients with ST-elevation myocardial infarction. However, there is evidence of improved outcomes with early administration of glycoprotein IIb/IIIa anatagonists as compared with administration in the catheterization laboratory.2 A Thrombolysis in Myocardial Infarction (TIMI) flow . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.